Outcomes with immune checkpoint inhibitors for relapsed small-cell lung cancer in a Swiss cohort
Autor: | Luciano Wannesson, Wolfram Jochum, H. Bouchaab, David König, Wolf-Dieter Janthur, Patrizia Frösch, Martin Früh, Alex Friedlaender, Sacha I. Rothschild, Laetitia A. Mauti, Alfredo Addeo, Izadora Demmer, Sämi Schär, Sabine Schmid, Christian Britschgi, Veronika Blum |
---|---|
Rok vydání: | 2020 |
Předmět: |
Adult
Male Oncology Cancer Research medicine.medical_specialty Lung Neoplasms Immunology Ipilimumab Antibodies Monoclonal Humanized 03 medical and health sciences 0302 clinical medicine Internal medicine Antineoplastic Combined Chemotherapy Protocols Biomarkers Tumor medicine Carcinoma Humans Immunology and Allergy Survival rate Aged Retrospective Studies business.industry Proportional hazards model Cancer Retrospective cohort study Middle Aged Prognosis medicine.disease Small Cell Lung Carcinoma Survival Rate Nivolumab Cohort Female Immunotherapy Neoplasm Recurrence Local business Switzerland Follow-Up Studies 030215 immunology medicine.drug |
Zdroj: | Cancer Immunology, Immunotherapy. 69:1605-1613 |
ISSN: | 1432-0851 0340-7004 |
Popis: | Early clinical trials showed promising outcomes with immune-checkpoint inhibitors (ICI) in a subset of patients with relapsed small-cell lung carcinoma (SCLC). The aim of this retrospective analysis was to assess the efficacy and safety of ICI for relapsed SCLC in a real-world patient population. Nine cancer centres in Switzerland contributed data to this cohort. Responses were assessed by the local investigators using standard RECIST v1.1 criteria. Progression-free survival (PFS) and overall survival (OS) were analysed by the Kaplan–Meier method. Associations between potential predictive markers and survival endpoints were probed by Cox proportional hazards. Forty-five patients were included in the analysis. Median age was 63 years, 73% were males and 18% had an ECOG performance status (PS) ≥ 2. ICIs were given as second-line treatment in 60%. Twenty-four patients (53%) received ipilimumab with nivolumab. Twenty-eight patients (62%) had undergone irradiation (RT) prior to or during ICI. Overall response rate (ORR) was 29% and median PFS and OS were 2.3 and 6.5 months, respectively. Median duration of response was 9 months (95% CI 2.8–NA). Five patients maintained their response for > 6 months, all of them receiving combination treatment. There were no new safety signals. This is the first report of “real-world” data on ICI in relapsed SCLC also including patients with poor PS. Promising durable responses were observed. No biological prognostic marker could be identified. |
Databáze: | OpenAIRE |
Externí odkaz: |